Replies to post #39947 on Inovio Pharmaceuticals Inc (INO)

[gew59]

From the article - monkeys. The results look to be preclinical and I have never seen an official % efficacy released from Inovio (the official source of info) for any phase of testing.
…….,
“INO-4800 is a plasmid DNA vaccine developed by Inovio Pharmaceuticals (USA) for preclinical testing within the ferret model of COVID-19. This DNA vaccine encoding the S protein was delivered by electroporation [33]. INO-4800 was able to reduce viral load in non-human primates; rhesus macaque, used as model, that received two doses (1 mg) for 4 weeks of the DNA vaccine showed humoral and cellular immune responses after 13 weeks [38]. The vaccine s+howed effectiveness against both D614 and G614 SARS-CoV-2 variants [38]. The study of safety, tolerability, and immunogenicity of INO-4800 for COVID-19 was tested in healthy volunteers using SARS-CoV-2 spike glycoprotein as antigen”